false
0001721484
0001721484
2024-07-17
2024-07-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 17, 2024
Longeveron Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-40060 |
|
47-2174146 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1951 NW 7th Avenue, Suite 520
Miami, Florida 33136
(Address of Principal Executive Offices)
Registrant’s Telephone Number, Including
Area Code: (305) 909-0840
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which registered |
Class
A Common Stock, $0.001 par value per share |
|
LGVN |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging Growth Company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events
On July 17, 2024, Longeveron Inc. (the “Company”)
issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for
the Company’s lead investigational product Lomecel-BTM, an allogeneic medicinal signaling cell therapy
product isolated from the bone marrow of young, healthy adult donors, for the treatment of mild Alzheimer’s disease. A copy of the
press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
Fast Track designation is available to a product
if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease
or condition (or serious aspect of a condition), and it demonstrates the potential to address unmet medical needs for such a disease or
condition (i.e., there is no available therapy for the condition, or the condition’s treatment or diagnosis is not adequately addressed
by currently available therapies). This designation is intended to facilitate development and expedite review of drugs to treat serious
and life-threatening conditions so that an approved product may reach the market expeditiously. Investigational therapies that receive
Fast Track designation may be eligible for Priority Review (i.e., review of an application within six (6) months of receipt versus 10
months) if relevant criteria are met at the time of application submission to the FDA, as well as rolling FDA review (i.e., the FDA may
consider reviewing portions of an application before the complete application is submitted).
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The exhibits listed in the following Exhibit Index are filed as part
of this Current Report on Form 8-K.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
LONGEVERON INC. |
|
|
Date: July 17, 2024 |
/s/ Wa’el Hashad |
|
Name: |
Wa’el Hashad |
|
Title: |
Chief Executive Officer |
2
Exhibit 99.1
![](https://www.sec.gov/Archives/edgar/data/1721484/000121390024061942/ex99-1_001.jpg)
Longeveron® Announces U.S. FDA Grants Fast
Track Designation for Lomecel-BTM for the Treatment of Mild Alzheimer’s Disease
– FDA designation
enables expedited clinical development and regulatory review timelines for Lomecel-B™ –
– Second designation received for Lomecel-BTM
for the treatment of mild Alzheimer’s Disease after Regenerative Medicine Advanced Therapeutics (RMAT) Designation announced on
July 9, 2024 –
– Phase 2a Lomecel-BTM data
in mild Alzheimer’s Disease selected for Featured Research Session oral presentation and poster presentation at upcoming Alzheimer’s
Association International Conference® (AAIC) –
MIAMI, July 17, 2024 -- Longeveron Inc. (NASDAQ:
LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related
conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lomecel-BTM
for the treatment of mild Alzheimer’s Disease. Lomecel-BTM is a proprietary, scalable, allogeneic, investigational cellular
therapy being evaluated across multiple indications, including Alzheimer’s Disease (Phase 2a completed), Aging-related Frailty (Phase
2b completed) and hypoplastic left heart syndrome (HLHS) (Phase 2b ongoing).
“Fast Track designation is another important
milestone for Longeveron and Lomecel-BTM, which, along with the recent granting of Regenerative Medicine Advanced Therapy (RMAT)
designation, recognizes the critical need to quickly advance novel, safe and effective investigational treatments for Alzheimer’s
Disease, which has a devastating impact on patients and their families,” said Wa’el Hashad, Chief Executive Officer of Longeveron.
“Alzheimer’s Disease is a neurodegenerative disorder that leads to progressive memory loss and death, and its tremendous impact
on our aging population is exacerbated by a lack of therapeutic options that slow disease progression or improve cognitive function. We
believe that Lomecel-BTM, which demonstrated an overall slowing/prevention of disease worsening compared to placebo in the
CLEAR MIND Phase 2a clinical trial, has the potential to become an important treatment option for physicians and patients, and we look
forward to sharing the latest data with the Alzheimer’s Disease research and patient communities at AAIC 2024.”
The FDA’s
Fast Track designation process is designed to facilitate the development and expedite the review of new therapies intended to treat
serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Investigational therapies that
receive Fast Track designation may be eligible for Priority Review if relevant criteria are met at the time of application submission
to FDA, and rolling FDA review.
The Fast Track designation granted to the Lomecel-BTM
Alzheimer’s Disease program is the fifth special regulatory designation received for Lomecel-BTM. The Lomecel-BTM
Alzheimer’s Disease program has also been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA, while the
Lomecel-BTM HLHS program has received three FDA designations: Orphan Drug designation, Fast Track designation and Rare Pediatric
Disease designation.
Upcoming Presentation at the Alzheimer’s Association International
Conference® (AAIC)
The Fast Track designation and continued clinical development of Lomecel-BTM
are based upon positive topline data reported from the Phase 2a CLEAR MIND clinical trial. Full results from the CLEAR MIND clinical trial
evaluating Lomecel-BTM in mild Alzheimer’s Disease have been selected for a Featured Research Session oral presentation
and poster presentation at AAIC, taking place July 28 – August 1, 2024, in Philadelphia and online. Longeveron Co-Founder, Chief
Scientific Officer and Chairman Joshua M. Hare, MD, FACC, FAHA, was invited to chair this Featured Research Session.
Details of the presentations at AAIC are as follows:
Oral Presentation
Date: Sunday, July 28, 2024
Time: 4:15 pm – 5:45pm EDT
Session: Featured Research Session, 1-32-FRS-B
Title: Results from a Phase 2a Proof-of-Concept Double-Blind,
Randomized, Placebo-Controlled Trial of Lomecel-BTM in Mild Alzheimer’s Disease Dementia
Poster Presentation
Date: Tuesday, July 30, 2024
Time: 7:30am – 4:15pm EDT
Session: In-Person Posters Tuesday; Drug Development
Topic: MRI Imaging results in the CLEAR MIND phase 2a clinical
trial of Lomecel-BTM
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company
developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™,
an investigational allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors.
Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue
repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three
pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s Disease, and Aging-related Frailty. Lomecel-BTM
development programs have received five separate and distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track
designation, and Rare Pediatric Disease designation; and, for the Alzheimer’s Disease program - Regenerative Medicine Advanced Therapy
(RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and
Instagram.
Forward-Looking Statements
Certain statements in this press release
that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance
and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated
by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as
“believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,”
“intend,” “on condition,” “target,” “see,” “potential,” “estimates,”
“preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy
or goals or other future events, circumstances, or effects and include, but are not limited to, the potential for Lomecel-BTM
to be an effective treatment for mild Alzheimer’s Disease or achieve U.S. FDA approval under the Fast Track designation program.
Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this
release include, but are not limited to, market and other conditions, our limited operating history and lack of products approved for
commercial sale; adverse global conditions, including macroeconomic uncertainty; inability to raise additional capital necessary to continue
as a going concern; our history of losses and inability to achieve profitability going forward; the absence of FDA-approved allogenic,
cell-based therapies for Aging-related Frailty, Alzheimer’s Disease, or other aging-related conditions, or for HLHS or other cardiac-related
indications; ethical and other concerns surrounding the use of stem cell therapy or human tissue; our exposure to product liability claims
arising from the use of our product candidates or future products in individuals, for which we may not be able to obtain adequate product
liability insurance; the adequacy of our trade secret and patent position to protect our product candidates and their uses: others could
compete against us more directly, which could harm our business and have a material adverse effect on our business, financial condition,
and results of operations; if certain license agreements are terminated, our ability to continue clinical trials and commercially market
products could be adversely affected; the inability to protect the confidentiality of our proprietary information, trade secrets, and
know-how; third-party claims of intellectual property infringement may prevent or delay our product development efforts; intellectual
property rights do not necessarily address all potential threats to our competitive advantage; the inability to successfully develop and
commercialize our product candidates and obtain the necessary regulatory approvals; we cannot market and sell our product candidates in
the U.S. or in other countries if we fail to obtain the necessary regulatory approvals; final marketing approval of our product candidates
by the FDA or other regulatory authorities for commercial use may be delayed, limited, or denied, any of which could adversely affect
our ability to generate operating revenues; we may not be able to secure and maintain research institutions to conduct our clinical trials;
ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations;
if we receive regulatory approval of Lomecel-B™ or any of our other product candidates, we will be subject to ongoing regulatory
requirements and continued regulatory review, which may result in significant additional expense; being subject to penalties if we fail
to comply with regulatory requirements or experience unanticipated problems with our therapeutic candidates; reliance on third parties
to conduct certain aspects of our preclinical studies and clinical trials; interim, “topline” and preliminary data from our
clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification
procedures that could result in material changes in the final data; the volatility of price of our Class A common stock; we could lose
our listing on the Nasdaq Capital Market; provisions in our certificate of incorporation and bylaws and Delaware law might discourage,
delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our Class
A common stock; we have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources
to successfully commercialize any products on our own or together with suitable collaborators; and in order to successfully implement
our plans and strategies, we will need to grow our organization, and we may experience difficulties in managing this growth. Further information
relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings
with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2023,
filed with the Securities and Exchange Commission on February 27, 2024, as amended by the Annual Report on Form 10-K/A filed March 11,
2024, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The forward-looking statements contained in this press
release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law,
to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
Media Contact:
Andrea Cohen
Sam Brown Inc. Healthcare Communications
andreacohen@sambrown.com
(917) 209-7163
v3.24.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Longeveron (NASDAQ:LGVNR)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Longeveron (NASDAQ:LGVNR)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024